- Home
- BFRG vs BLRX Comparison
BFRG vs BLRX Comparison
Compare BFRG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRG | BLRX |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 12.9M |
| IPO Year | 2023 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BFRG | BLRX |
|---|---|---|
| Price | $1.12 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 68.3K | 27.3K |
| Earning Date | 11-14-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $116,670.00 | ★ $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $2.30 |
| 52 Week High | $4.84 | $14.70 |
Technical Indicators
Market Signals| Indicator | BFRG | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.78 | 42.76 |
| Support Level | $0.98 | $2.87 |
| Resistance Level | $1.21 | $3.36 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 63.71 | 41.08 |
Price Performance
Historical ComparisonAbout BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.